Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest inflammatory diseases Stories

2014-02-19 08:31:28

Proceeds Bring Series B to CHF 44.9 Million ZURICH-SCHLIEREN, Switzerland, Feb. 19, 2014 /PRNewswire/ -- Covagen today announced it has added Baxter Ventures as an investor in its Series B financing round raising the total to CHF 44.9 million. The Series B includes an option for all existing investors to invest an additional CHF 14 million in the future potentially increasing the total amount of this financing round to CHF 58.9 million. The additional financing will primarily...

2013-08-26 00:20:28

Common Stock Trading on Nasdaq OMX Stockholm Exchange and OTCQX Trading Platform TARRYTOWN, N.Y., Aug. 26, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (Nasdaq OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) (the "Company") announced today the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation. The merger combines Immune's antibody therapeutic platform focused on the treatment of inflammatory diseases and cancer with EpiCept's early stage cancer...

2013-03-13 08:33:33

Up to 63% Reduction in CRP Response with ISIS-CRP Rx Treatment CARLSBAD, Calif., March 13, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that ISIS-CRP(Rx) selectively reduced severe elevations in C-reactive protein (CRP) in humans. Data from a Phase 1 clinical study showed that ISIS-CRP(Rx) produced statistically significant, dose-dependent reductions in CRP response following an endotoxin challenge, which produces immune responses similar to those...

2012-09-10 02:28:32

GAITHERSBURG, Md. and SHANGHAI, Sept. 10, 2012 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, and WuXi AppTec, a leading research and development outsourcing company, today announced that they have formed a joint venture to develop and commercialize MEDI5117, a novel biologic for autoimmune and inflammatory diseases, in China. MedImmune will provide technical and development expertise, while WuXi AppTec will provide local regulatory, manufacturing, pre-clinical and...

2012-06-14 06:24:15

AACHEN, Germany, June 14, 2012 /PRNewswire/ -- New chemical entities (NCE) in the areas of pain and inflammation as well as the formulation technology platform INTAC(TM) are at the core of Grunenthal's presentation at BIO International Convention 2012. The company - which has proven to be successful in bringing innovation to the market - invites the pharmaceutical community to learn about new assets evolving from its research. More than 20,000 participants are expected to attend BIO 2012, the...

2012-03-12 20:07:14

Cedars-Sinai researchers have unlocked the mystery of how an inflammatory molecule is produced in the body, a discovery they say could lead to advances in the treatment of rheumatoid arthritis, Type 2 diabetes and numerous other chronic diseases that affect tens of millions of people. The study, funded by the National Institutes of Health, is published online by the peer-reviewed journal Immunity and will appear in the March print edition. The researchers identified for the first time...

2012-01-23 08:00:00

JERUSALEM, Jan. 23, 2012 /PRNewswire/ -- Hadasit Bio-Holdings (TASE: HDST, OTC: HADSY) a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed. Enlivex is developing an innovative drug treatment for autoimmune diseases - diseases in which the...

2011-08-17 08:52:00

NEW YORK, Aug. 17, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed by the Hadassah University Hospital, Israel's foremost medical research center, announced that its portfolio company Enlivex Therapeutics (92% owned by Hadasit Bio) has completed the recruitment of three out of four groups in its Phase I / II clinical trial using its treatment for the reduction of graft versus...

2011-08-04 14:16:00

SAN DIEGO, Aug. 4, 2011 /PRNewswire/ -- Genelux Corporation, a privately held, clinical stage biopharmaceutical company developing diagnostic and therapeutic solutions for cancer and inflammatory diseases, today announced the appointment of Dr. Catherine J. Mackey, long-time Pfizer executive, to the Company's Board of Directors. "In a career defined by excellence at every level, Dr. Mackey brings a unique set of skills and attributes that we believe will significantly complement and...

2011-07-26 13:59:25

Pharmacists of the University Jena analyze why men suffer more rarely from inflammatory diseases than women It's all down to the testosterone: men are usually more muscular than women, they have deeper voices and more body hair. And "“ men are less susceptible to inflammatory diseases and allergies than women. This is also due to the male sex hormones as pharmacists at the Friedrich Schiller University Jena (Germany) have shown in a recent study. "It is mostly women who are affected by...